Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 2.17 USD -1.81% Market Closed
Market Cap: 211.8m USD

Wall Street
Price Targets

EDIT Price Targets Summary
Editas Medicine Inc

Wall Street analysts forecast EDIT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EDIT is 5.04 USD with a low forecast of 1.01 USD and a high forecast of 13.65 USD.

Lowest
Price Target
1.01 USD
53% Downside
Average
Price Target
5.04 USD
132% Upside
Highest
Price Target
13.65 USD
529% Upside
Editas Medicine Inc Competitors:
Price Targets
ORY
Oryzon Genomics SA
130% Upside
CNTB
Connect Biopharma Holdings Ltd
200% Upside
BNTX
BioNTech SE
47% Upside
RNA
Avidity Biosciences Inc
3% Upside
ABNX
Abionyx Pharma SA
213% Upside
1801
Innovent Biologics Inc
33% Upside
CHRS
Coherus BioSciences Inc
335% Upside
CMPX
Compass Therapeutics Inc.
143% Upside

Revenue
Forecast

Revenue Estimate
Editas Medicine Inc

The compound annual growth rate of Editas Medicine Inc's revenue for the next 4 years is -23%.

N/A
Past Growth
-23%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Editas Medicine Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat

Net Income
Forecast

Net Income Estimate
Editas Medicine Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EDIT's stock price target?
Price Target
5.04 USD

According to Wall Street analysts, the average 1-year price target for EDIT is 5.04 USD with a low forecast of 1.01 USD and a high forecast of 13.65 USD.

What is Editas Medicine Inc's Revenue forecast?
Projected CAGR
-23%

The compound annual growth rate of Editas Medicine Inc's revenue for the next 4 years is -23%.

Back to Top